Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bio-Techne Corporation stock

Own Bio-Techne Corporation stock in just a few minutes.

Fact checked

Bio-Techne Corporation is a biotechnology business based in the US. Bio-Techne Corporation shares (TECH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio-Techne Corporation employs 2,300 staff and has a trailing 12-month revenue of around USD$738.7 million.

How to buy shares in Bio-Techne Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Bio-Techne Corporation. Find the stock by name or ticker symbol: TECH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bio-Techne Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Bio-Techne Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Bio-Techne Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Bio-Techne Corporation share price

Use our graph to track the performance of TECH stocks over time.

Bio-Techne Corporation shares at a glance

Information last updated 2020-10-20.
52-week rangeUSD$155.17 - USD$286.68
50-day moving average USD$251.928
200-day moving average USD$251.9229
Wall St. target priceUSD$299.33
PE ratio 45.6478
Dividend yield USD$1.28 (0.48%)
Earnings per share (TTM) USD$5.82

Buy Bio-Techne Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bio-Techne Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Bio-Techne Corporation under- or over-valued?

Valuing Bio-Techne Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Techne Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bio-Techne Corporation's P/E ratio

Bio-Techne Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 46x. In other words, Bio-Techne Corporation shares trade at around 46x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Bio-Techne Corporation's PEG ratio

Bio-Techne Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.511. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Techne Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Bio-Techne Corporation's EBITDA

Bio-Techne Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$199 million.

The EBITDA is a measure of a Bio-Techne Corporation's overall financial performance and is widely used to measure a its profitability.

Bio-Techne Corporation financials

Revenue TTM USD$738.7 million
Operating margin TTM 20.41%
Gross profit TTM USD$483.2 million
Return on assets TTM 4.82%
Return on equity TTM 18.01%
Profit margin 31.04%
Book value $35.919
Market capitalisation USD$10.3 billion

TTM: trailing 12 months

Shorting Bio-Techne Corporation shares

There are currently 585,113 Bio-Techne Corporation shares held short by investors – that's known as Bio-Techne Corporation's "short interest". This figure is 2.7% up from 569,507 last month.

There are a few different ways that this level of interest in shorting Bio-Techne Corporation shares can be evaluated.

Bio-Techne Corporation's "short interest ratio" (SIR)

Bio-Techne Corporation's "short interest ratio" (SIR) is the quantity of Bio-Techne Corporation shares currently shorted divided by the average quantity of Bio-Techne Corporation shares traded daily (recently around 187536.21794872). Bio-Techne Corporation's SIR currently stands at 3.12. In other words for every 100,000 Bio-Techne Corporation shares traded daily on the market, roughly 3120 shares are currently held short.

However Bio-Techne Corporation's short interest can also be evaluated against the total number of Bio-Techne Corporation shares, or, against the total number of tradable Bio-Techne Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bio-Techne Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Bio-Techne Corporation shares in existence, roughly 20 shares are currently held short) or 0.017% of the tradable shares (for every 100,000 tradable Bio-Techne Corporation shares, roughly 17 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bio-Techne Corporation.

Find out more about how you can short Bio-Techne Corporation stock.

Bio-Techne Corporation share dividends


Dividend payout ratio: 28.26% of net profits

Recently Bio-Techne Corporation has paid out, on average, around 28.26% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.48% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bio-Techne Corporation shareholders could enjoy a 0.48% return on their shares, in the form of dividend payments. In Bio-Techne Corporation's case, that would currently equate to about $1.28 per share.

While Bio-Techne Corporation's payout ratio might seem fairly standard, it's worth remembering that Bio-Techne Corporation may be investing much of the rest of its net profits in future growth.

Bio-Techne Corporation's most recent dividend payout was on 28 August 2020. The latest dividend was paid out to all shareholders who bought their shares by 17 August 2020 (the "ex-dividend date").

Have Bio-Techne Corporation's shares ever split?

Bio-Techne Corporation's shares were split on a 2:1 basis on 4 December 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bio-Techne Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Bio-Techne Corporation shares which in turn could have impacted Bio-Techne Corporation's share price.

Bio-Techne Corporation share price volatility

Over the last 12 months, Bio-Techne Corporation's shares have ranged in value from as little as $155.17 up to $286.68. A popular way to gauge a stock's volatility is its "beta".

TECH.US volatility(beta: 0.98)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Techne Corporation's is 0.9763. This would suggest that Bio-Techne Corporation's shares are less volatile than average (for this exchange).

Bio-Techne Corporation overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site